News

Quest Diagnostics price target raised to $198 from $190 at BofA
BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and ...
Zacks Investment Research on MSN10h
Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?
The market expects Quest Diagnostics (DGX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...
Zacks Investment Research on MSN10h
Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings
Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...